Literature DB >> 27292046

COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No.

Kevin K Brown1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27292046     DOI： 10.1016/j.chest.2016.04.036

Source DB:  PubMed          Journal:  Chest        ISSN： 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  4 in total

1.  Unwinding the Collagen Fibrils: Elucidating the Mechanism of Pirfenidone and Nintedanib in Pulmonary Fibrosis.

Authors:  Harinath Bahudhanapati; Daniel J Kass
Journal:  Am J Respir Cell Mol Biol       Date:  2017-07       Impact factor: 6.914

2.  3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.

Authors:  Ranu Surolia; Fu Jun Li; Zheng Wang; Huashi Li; Gang Liu; Yong Zhou; Tracy Luckhardt; Sejong Bae; Rui-Ming Liu; Sunad Rangarajan; Joao de Andrade; Victor J Thannickal; Veena B Antony
Journal:  JCI Insight       Date:  2017-01-26

Review 3.  The diagnosis of idiopathic pulmonary fibrosis: current and future approaches.

Authors:  Fernando J Martinez; Alison Chisholm; Harold R Collard; Kevin R Flaherty; Jeffrey Myers; Ganesh Raghu; Simon L F Walsh; Eric S White; Luca Richeldi
Journal:  Lancet Respir Med       Date:  2016-12-06       Impact factor: 30.700

4.  Caveolin-1 gene therapy inhibits inflammasome activation to protect from bleomycin-induced pulmonary fibrosis.

Authors:  Xin Lin; Michael Barravecchia; R Matthew Kottmann; Patricia Sime; David A Dean
Journal:  Sci Rep       Date:  2019-12-23       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.